Why payment integrity is a game changer

By Bruce Shutan – Forward-thinking advisers are increasingly connecting their self-insured employer clients with independent payment-integrity solutions to better comply with price-transparency laws and regulations, and become better stewards of the benefits they offer. Payment integrity combines technology, analytics, clinical expertise and auditing to ensure that healthcare claims are paid accurately by identifying and preventing fraud, waste, abuse, billing errors and contract noncompliance. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Advisers are steering self-insured employers toward independent payment-integrity vendors: The article says advisers are increasingly connecting clients with independent solutions as employers try to align with price-transparency rules and stronger stewardship of benefit spending. It frames payment integrity as a mix of technology, analytics, clinical review and auditing used to ensure claims are paid correctly. The underlying goal is to identify and prevent issues such as fraud, waste, abuse, billing mistakes and contract noncompliance. The piece suggests this approach can also help advisers differentiate themselves when competing for cost-focused employer clients.

2. Data access and contract terms with insurer-owned TPAs are presented as major obstacles: A Willis Towers Watson benefits leader cited in the article says some administrative-services-only contracts with insurer-owned TPAs can restrict sharing health plan data with self-insured employers. The article characterizes this as a potential “red flag” for employers trying to oversee how claims are paid and to monitor service providers under ERISA. It also notes that these arrangements can introduce conflicts tied to vertical integration (e.g., insurer ownership of TPAs and other benefit entities). The discussion implies employers may push for clearer, broader access to their own plan data to support defensible oversight.

3. A shift toward prepayment claim review is highlighted as an emerging direction: The article describes growing emphasis on adjudicating claims on a prepayment basis rather than relying primarily on post-payment recoveries. It presents post-payment recoupment as challenging when carriers won’t provide needed data or providers resist returning funds. One source argues prepayment capabilities matter because they can intercept problems earlier in the claims process. The piece also suggests that insurer involvement can limit what’s possible pre-adjudication, while noting the market is still evolving and that contract expectations may change under pressure from employers, brokers and ERISA attorneys.

Aflac US sales grow amid climbing voluntary benefits claims costs

By Mark Rosanes – Aflac Incorporated posted stronger US supplemental health sales in the second quarter of 2026, but a sharp rise in claims costs squeezed margins. Employer health benefit costs are climbing at their fastest rate in 15 years. That pressure is bearing down on both carriers and the brokers who place their products. Read Full Article...

HVBA Article Summary

1. US premium and sales growth, led by voluntary benefits: Aflac reported higher US net earned premiums and increased new annualized premium sales in Q2 2026. The company said growth was concentrated in group voluntary benefits along with network dental and vision products. This indicates demand for employer-adjacent supplemental offerings continued even as broader benefit costs increased.

2. Profitability pressure from higher claims costs: Despite the sales gains, Aflac’s US segment saw pretax adjusted earnings decline and its profit margin narrow in the quarter. The benefits and claims ratio increased to 49.5% of net earned premiums, reflecting higher claims costs relative to premium intake. The same pattern continued into the first half of 2026, with premiums rising while margins tightened.

3. Consolidated results affected by currency and capital returns continued: Companywide revenue and adjusted earnings were lower year over year, with management attributing part of the decline to a weaker yen versus the dollar. Aflac quantified the currency move’s impact on adjusted earnings per share and also provided a currency-neutral comparison for the first six months. The firm also reported returning $1.3 billion to shareholders in Q2 through share repurchases and dividends and announced the next quarterly dividend.

Price transparency was supposed to change health care, but did it?

By Deborah Ault – When hospital price transparency regulations took effect in 2021, policymakers promised a new era of health care purchasing. Patients would finally know what care costs before receiving it. Employers would become more sophisticated purchasers. Competition would increase, markets would function more efficiently, and health care spending would begin to moderate. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Compliance has not translated into practical usability: The piece argues that many organizations met the technical requirements of price transparency by publishing machine-readable files and large data sets, but that these materials are difficult for employers and patients to interpret. It describes a gap between making information available and making it actionable for real purchasing decisions. The author frames this as meeting the letter of the regulation while missing its intent, leaving buyers still uncertain about whether they are overpaying or how to compare options.

2. Price alone is an incomplete—and sometimes misleading—signal: The article emphasizes that purchasers often equate higher prices with higher quality, which can be a reasonable instinct in other markets but not necessarily in health care. It contends that value depends on both cost and outcomes, and that transparency initiatives focused too heavily on price without pairing it with meaningful quality measures. In fee-for-service settings, the author notes that higher-quality providers can sometimes reduce total costs by avoiding complications, readmissions, and unnecessary care.

3. A shift in measurement is needed to judge whether transparency worked: Rather than evaluating success based on whether hospitals posted files online, the author suggests assessing whether behavior actually changed for employers, employees, patients, and brokers. The article asks whether employers redesigned networks, whether employees made different choices, and whether patients sought care earlier due to clearer expectations of what they would owe. It concludes that without understandable, decision-ready information connected to quality, transparency risks becoming “compliance theater” rather than a driver of better purchasing.

Same Knee Surgery, Twice the Price: Hospital Monopolies Push Up Healthcare Costs

By Peter Whoriskey – More than a million times a year, a U.S. surgeon slices open a knee, strips out worn cartilage, caps the leg bones with metal, and drops in a plastic spacer to allow the new joint to glide. While knee replacement procedures have become standard, the prices charged have not. At Catawba Valley Medical Center in Hickory, North Carolina, for example, the cost of the procedure under a Blue Cross Blue Shield health plan this year was about $16,000, according to data from Serif Health, a San Francisco startup that collects recently released data from hospitals and insurers. Little more than an hour's drive west, however, at Mission Hospital in Asheville, the cost of the procedure under the same health plan was around $40,000, or more than double, the data showed. Formed by the merger of the two largest hospitals in the region, Mission has little competition and more power to demand the higher price. Read Full Article...

HVBA Article Summary

1. Price transparency is making consolidation’s effects easier to quantify: The article describes how newly available hospital price data can be used to compare what different facilities negotiate with the same insurer for the same procedure. It notes that the Centers for Medicare & Medicaid Services began requiring hospitals to disclose prices in 2021, enabling companies like Serif Health to compile broader datasets. That visibility changes a long-standing dynamic in which hospital prices were difficult for the public to observe and compare. The piece argues this helps illustrate how market power can translate into higher negotiated rates.

2. Policy responses to hospital mergers are evolving but uneven: The story outlines shifting federal approaches to challenging healthcare consolidation, including the revocation of a prior executive-order directive encouraging more aggressive merger enforcement and a later FTC memo calling for a healthcare-merger task force. It also describes state-level actions that aim to strengthen oversight or limit anticompetitive deals, citing examples from Minnesota, California, and Oregon. Despite these moves, the article says the overall consolidation trend continues as systems pursue scale and negotiating leverage. The piece presents this as an ongoing tension between allowing integration and preventing monopoly-like pricing power.

3. Local experience in Asheville is presented as a case study in monopoly dynamics: The article uses Mission Hospital’s history—created by the merger of two major hospitals and later acquired by HCA—to illustrate how a dominant system can affect both pricing and perceptions of care quality. It includes accounts from patients and employers who say the lack of alternative hospitals leaves them little ability to avoid the system’s prices and contracts. The piece also references regulatory findings and academic research discussed in the text that link limited competition to potential quality concerns. Overall, Asheville is portrayed as an example of how consolidation can reshape a regional healthcare market for residents, employers, and insurers.

Why There's a Shortage of Chemotherapy Drugs

By Veronique Greenwood – When cisplatin came on the market in 1978, it revolutionized cancer care. Carboplatin, a related chemotherapy drug with fewer side effects, soon followed in 1986. Together, these two drugs have saved countless lives and are prescribed for up to 20% of cancer patients to treat ovarian, bladder, breast, lung, and other types of cancer. “They're the backbone for treatments for a lot of different types of cancer,” says Dr. Jacob Reibel, a medical oncologist at Dartmouth Cancer Center. Read Full Article...

HVBA Article Summary

1. Shortages are persisting longer, not cycling quickly: Sources quoted in the article describe drug shortages as increasingly long-lived, with many remaining unresolved from prior years rather than being newly created. The piece points to a broad trend across medicines, not just oncology drugs, in which disruptions last much longer than they used to. This framing suggests the issue is structural within supply chains rather than a one-off manufacturing mishap.

2. Generic pricing and purchasing practices can discourage production: The article explains that many shortage-hit chemotherapy drugs are off-patent generics that still require specialized sterile manufacturing capacity. It describes hospitals and group-purchasing organizations as prioritizing the lowest upfront prices, while contracts may not guarantee volumes that help manufacturers plan sustainable output. As a result, manufacturers may shift production lines toward higher-margin drugs when finances tighten, reducing supply of essential chemo agents.

3. Concentration of manufacturing and inputs increases fragility, prompting proposals for new models: The article ties vulnerability to reliance on a small number of factories and to internationally concentrated sources of key materials, which can be disrupted by quality-control problems or geopolitical events. It highlights efforts to build more resilient domestic or utility-style production (such as nonprofit manufacturing initiatives) and to diversify sourcing to add redundancy. Experts quoted argue that contract reforms, nearer-to-need manufacturing, and broader supply-chain diversity are needed to reduce the risk that treatment plans are altered due to unavailable drugs.

Insurers thought the threat to cyber was bad from AI. Now even OpenAI is scared

By Matthew Sellers – For months, cyber underwriters have priced in the assumption that artificial intelligence would sharpen attackers' tools faster than it sharpened insurers' defenses. On August 7, OpenAI more or less confirmed that fear itself. The ChatGPT maker said it had halted parts of the internal development of an unreleased model, code-named Astra, after concluding it could not rule out that the system had reached "critical" cybersecurity capability, the highest tier defined under the company's own Preparedness Framework. No OpenAI model has come this close to that threshold before. The company said the finding followed only a few days of internal testing that showed sharp gains in agentic coding and hacking ability. Read Full Article...

HVBA Article Summary

1. OpenAI pauses Astra over internal risk classification: OpenAI said it stopped parts of development on its unreleased model “Astra” after internal work indicated it could be at the company’s “critical” cybersecurity tier. In its framework, “critical” implies the potential for autonomous exploitation of hardened targets rather than tool-assisted or human-directed activity. The company described the trigger as short internal testing that showed rapid improvement in agentic coding and hacking-related capability.

2. “Critical” capability is defined around autonomous end-to-end attacks and zero-days: OpenAI’s Preparedness Framework describes the critical tier as a model being able to independently identify and build working exploits for severe, previously unknown vulnerabilities (zero-days) in real-world systems. It also includes the ability to take a broad objective and plan and execute a full cyberattack against a well-defended target without step-by-step human guidance. The article frames this threshold as a notable escalation relative to what insurers have typically considered when pricing AI-related cyber risk.

3. A sequence of recent incidents is shifting underwriting and disclosure expectations: The article connects Astra’s flag to other recent frontier-model events, including an OpenAI/Hugging Face incident attributed to a misconfigured network setting and separate disclosures by Anthropic involving models reaching outside testing boundaries. It argues that these kinds of disclosures may become more common, affecting how carriers treat “AI risk” in renewals. It also cites growing regulatory attention and broker/industry indicators (such as Allianz’s Risk Barometer movement) as signals that AI is being treated less as a distant exposure and more as a current risk factor.

FDA proposes mandatory food ingredient reporting

By Tina Reed – The Trump administration on Monday proposed requiring food companies to tell the Food and Drug Administration when they determine ingredients are safe to eat and doing away with an oft-criticized voluntary notification program. Read Full Article...

HVBA Article Summary

1. Shift from voluntary to mandatory disclosure: The proposal would require companies to notify the FDA when they conclude an ingredient is “generally recognized as safe” (GRAS), addressing a long-standing criticism that the current system leaves regulators in the dark. Officials argued this would improve transparency about what enters the food supply. However, the proposal as described leaves open how the FDA would respond when it identifies questionable ingredients. The lack of detail raises uncertainty about practical impact beyond reporting.

2. Legal and capacity limits may constrain enforcement: The article notes that the administration’s ability to tighten oversight appears limited by existing federal law, with further steps potentially requiring congressional action. Former FDA commissioner Scott Gottlieb is cited as saying the agency has gone as far as it can without new legislation. Separately, Marion Nestle questioned whether the FDA has sufficient qualified staff to review disclosures, given staffing reductions and hiring challenges. These constraints suggest implementation and follow-through could be significant hurdles.

3. Debate over ultra-processed foods definition and industry response: Kennedy said HHS and USDA submitted the federal government’s first definition of ultra-processed foods for final review, but the definition was not made public. Nutrition and consumer groups expressed skepticism that companies could continue selling products without premarket review, and they questioned how deadlines and enforcement would work under the proposal. The food industry argued federal changes are preferable to state-by-state rules and warned that defining ultra-processed foods could confuse consumers and raise grocery costs. An industry representative, Rhonda Bentz of the Consumer Brands Association, criticized the definition effort in a linked statement.

GLP-1s push health plan costs to 15-year high

By Jimmy Nesbitt – The growing popularity of expensive GLP-1 drugs is helping push employer-sponsored health plan costs to their fastest growth rate in 15 years for 2027, according to a new survey. Medical plan costs are projected to rise nearly 10% next year, according to the 2027 Segal Health Plan Cost Trend Survey. Prescription drug costs are forecast to climb even faster, at 11.5%. "Employers aren't facing a temporary spike in pharmacy costs but instead a consistent, year-over-year growth," said Matt Nguyen, vice president and health informatics consultant at Segal. "We're seeing a structural shift right now, driven by these drugs." Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. GLP-1 Coverage Is Significantly Increasing Pharmacy Cost Trends: Segal data found prescription drug costs rose 18.3% in 2025 for employer plans covering GLP-1s for obesity, with GLP-1 drugs responsible for 7.8 percentage pointsof that increase. Plans covering GLP-1s only for diabetes experienced a lower 10.5% increase, with the drugs contributing just 1.2 percentage points. With roughly 40% of U.S. adults classified as obese and another 25%–30% overweight, the large eligible population combined with annual treatment costs of $10,000–$15,000 creates significant affordability concerns.

2. Employers Are Using Multiple Strategies to Manage GLP-1 Spending: The most common cost-management approaches include step therapy and prior authorization, requiring patients to try lower-cost treatments or meet certain criteria before receiving GLP-1 therapy. Other employers require participation in lifestyle modification programs, exclude weight-loss coverage altogether, impose higher BMI eligibility thresholds, or increase employee cost-sharing. However, step therapy may have limitations because newer GLP-1 medications can produce 10%–20% weight loss within six to 12 months, compared with approximately 2%–5% for earlier-generation treatments.

3. Long-Term Affordability May Require More Integrated Benefits Management: Segal expects expanding GLP-1 utilization to remain a significant pharmacy cost driver, creating pressure for employers seeking to balance access with sustainable plan spending. According to Segal, some employers achieving better management results have closely integrated their medical and pharmacy benefits rather than treating GLP-1 utilization solely as a pharmacy issue. The findings suggest employers will continue evaluating coverage criteria, clinical management, and benefit design as utilization and costs evolve.